The effect of a geriatric oncology (GO) evaluation on treatment (Tx) decisions for older patients (pts) with cancer in Mexico.

Authors

Haydee Verduzco-Aguirre

Haydee Cristina Verduzco-Aguirre

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Ciudad De México, Mexico

Haydee Cristina Verduzco-Aguirre , Ana Patricia Navarrete Reyes , Nora Ivonne Reyes Martinez , Jose de Jesus Ruiz Lopez , Odin Vazquez Valdez , Juan Cuadros Moreno , Juan Miguel Antonio Garcia Lara , Yanin Chavarri Guerra , Eucario Leon Rodriguez , Jose Alberto Avila Funes , Enrique Soto Perez De Celis

Organizations

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Ciudad De México, Mexico, Cancer Care in the Elderly Clinic, Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, DELEGACION TLALPAN, MA, MX, Department of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

Research Funding

Other

Background: GO evaluations may lead to improvements in the care of older adults with cancer, but their effect on Tx decisions in everyday clinical practice needs further research. Our goal was to describe the effect of GO evaluations on Tx decisions in the first GO clinic implemented in Mexico. Methods: The records of 173 pts aged ≥65 years (y) referred to our GO Clinic before active Tx initiation from 05/15 to 10/17 were reviewed. Pts were screened with a validated tool (G8; Soubeyran et al, 2011); those deemed vulnerable (score ≤14) underwent a full geriatric assessment; and Tx recommendations were sent to the treating oncologist. We measured the proportion of patients in which there was agreement between GO recommendations and final Tx decisions, and assessed whether agreement increased in cases in which the treating oncologist’s notes mentioned the GO evaluation. Results: Median age was 79 y (range 64-97). 37% of pts had genitourinary and 32% gastrointestinal malignancies; 42% were stage IV. Proposed Tx before GO evaluation included palliative chemotherapy (CT) (32%), curative surgery/radiotherapy (31%), and neo/adjuvant CT (19%). A recommendation to administer standard Tx was made in 47% of cases, less intensive Tx in 32%, and best supportive care (BSC) in 20%. The treating oncologist’s final Tx decision matched the GO recommendation for 81% of pts, and GO recommendations were mentioned in the treating oncologist’s notes in 62% of cases. Agreement between the treating oncologist & GO clinic was higher when BSC was recommended (94%), followed by standard Tx (77%), and less intensive Tx (75%). Agreement between the treating oncologist & GO clinic was 84% when the GO evaluation was mentioned, compared to 75% when it wasn't (p = 0.16). In pts for which less intensive Tx was recommended (n = 56), agreement was 84% when the GO evaluation was mentioned, compared with 56% when it wasn't (p = 0.04). Conclusions: Agreement between GO recommendations and final Tx decisions was high, especially for cases in which BSC was recommended. Including GO evaluations in everyday clinical practice may provide useful information to guide oncologists caring for older pts, particularly when considering less intensive therapy.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Patient and Survivor Care

Track

Patient and Survivor Care

Sub Track

Geriatric Oncology

Citation

J Clin Oncol 36, 2018 (suppl; abstr 10046)

DOI

10.1200/JCO.2018.36.15_suppl.10046

Abstract #

10046

Poster Bd #

34

Abstract Disclosures